These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 24038032)

  • 1. Number needed to treat for time-to-event data with competing risks.
    Gouskova NA; Kundu S; Imrey PB; Fine JP
    Stat Med; 2014 Jan; 33(2):181-92. PubMed ID: 24038032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inference for cumulative incidence quantiles via parametric and nonparametric approaches.
    Lee M; Fine JP
    Stat Med; 2011 Nov; 30(27):3221-35. PubMed ID: 21898525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applying k-sample tests to conditional probabilities for competing risks in a clinical trial.
    Lunn M
    Biometrics; 1998 Dec; 54(4):1662-72. PubMed ID: 9988543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer: the need for more clinical research.
    Hayward RL; Dixon JM
    Surg Oncol; 2003 Dec; 12(4):289-304. PubMed ID: 14998569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adjuvant tamoxifen duration: more large-scale randomized evidence is needed].
    Davies C; Nomura Y; Ohashi Y
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1203-9. PubMed ID: 9279337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct likelihood inference and sensitivity analysis for competing risks regression with missing causes of failure.
    Moreno-Betancur M; Rey G; Latouche A
    Biometrics; 2015 Jun; 71(2):498-507. PubMed ID: 25761785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients.
    Bria E; Ciccarese M; Giannarelli D; Cuppone F; Nisticò C; Nuzzo C; Natoli G; Fabi A; Terzoli E; Cognetti F; Carlini P
    Cancer Treat Rev; 2006 Aug; 32(5):325-32. PubMed ID: 16766125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A missing data approach to semi-competing risks problems.
    Dignam JJ; Wieand K; Rathouz PJ
    Stat Med; 2007 Feb; 26(4):837-56. PubMed ID: 16755544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of cumulative incidence function under the proportional hazards model.
    Cheng SC; Fine JP; Wei LJ
    Biometrics; 1998 Mar; 54(1):219-28. PubMed ID: 9544517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01.
    Sacco M; Valentini M; Belfiglio M; Pellegrini F; De Berardis G; Franciosi M; Nicolucci A;
    J Clin Oncol; 2003 Jun; 21(12):2276-81. PubMed ID: 12805326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cumulative incidence in competing risks data and competing risks regression analysis.
    Kim HT
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):559-65. PubMed ID: 17255278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer.
    Hackshaw A; Roughton M; Forsyth S; Monson K; Reczko K; Sainsbury R; Baum M
    J Clin Oncol; 2011 May; 29(13):1657-63. PubMed ID: 21422412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
    Strasser-Weippl K; Badovinac-Crnjevic T; Fan L; Goss PE
    Breast; 2013 Aug; 22 Suppl 2():S171-5. PubMed ID: 24074782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyses of cumulative incidence functions via non-parametric multiple imputation.
    Ruan PK; Gray RJ
    Stat Med; 2008 Nov; 27(27):5709-24. PubMed ID: 18712779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
    Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
    J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits.
    Brewster AM; Christo DK; Lai H; Helzlsouer K
    Cancer; 2005 Mar; 103(6):1147-53. PubMed ID: 15674856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant endocrine therapy for breast cancer: more questions than answers.
    Ellis MJ
    J Clin Oncol; 2005 Aug; 23(22):4842-4. PubMed ID: 15998901
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.